Claims for Patent: 10,023,628

Summary for Patent: 10,023,628

Title:	Cell line expressing single chain factor VIII polypeptides and uses thereof
Abstract:	The present invention provides cell lines for producing single chain FVIII polypeptides, e.g., chimeric single chain FVIII polypeptides, methods of producing single chain FVIII polypeptides, single chain FVIII polypeptides, and methods of treating Hemophilia A with a single chain Factor VIII polypeptide.
Inventor(s):	Low; Susan (Pepperell, MA), Dumont; Jennifer A. (Groton, MA), Bitonti; Alan J. (Acton, MA)
Assignee:	Bioverativ Therapeutics Inc. (Waltham, MA)
Application Number:	14/412,823
Patent Claims:	1. An isolated cell line comprising a recombinant vector encoding a single chain FVIII polypeptide, wherein the single chain FVIII polypeptide comprises residues 20 to 1457 of SEQ ID NO: 8. 2. The cell line of claim 1, wherein the single chain FVIII polypeptide further comprises a heterologous moiety. 3. A polynucleotide encoding the single chain FVIII polypeptide of claim 1. 4. A vector comprising the polynucleotide of claim 3. 5. The cell line of claim 1, wherein the cell line is a mammalian cell line. 6. The cell line of claim 2, wherein the heterologous moiety is a half-life extending moiety. 7. The cell line of claim 6, wherein the half-life extending moiety is an immunoglobulin constant region or a portion thereof, albumin, albumin binding polypeptide, PAS, the C-terminal peptide (CTP) of the .beta. subunit of human chorionic gonadotropin, polyethylene glycol (PEG), hydroxyethyl starch (HES), albumin-binding small molecules, or combinations thereof. 8. The cell line of claim 1, wherein the cell line further comprises a polynucleotide specific for a FVIII polypeptide processing enzyme. 9. The cell line of claim 1, wherein the single chain FVIII polypeptide further comprises an immunoglobulin constant region or a portion thereof. 10. The cell line of claim 1, wherein the single chain FVIII polypeptide further comprises albumin. 11. A polynucleotide encoding the single chain FVIII polypeptide and the half-life extending moiety of claim 6. 12. A vector comprising the polynucleotide of claim 11. 13. A polynucleotide encoding the single chain FVIII polypeptide and the immunoglobulin constant region or a portion thereof of claim 9. 14. A vector comprising the polynucleotide of claim 13. 15. An isolated cell line comprising a recombinant vector encoding the amino acid sequence as set forth in SEQ ID NO: 8. 16. A vector encoding the amino acid sequence as set forth in SEQ ID NO: 8. 17. A method for producing a single chain FVIII polypeptide comprising culturing the cell line of claim 1 under conditions sufficient for production of the single chain FVIII polypeptide.

Details for Patent 10,023,628

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	January 15, 1974	10,023,628	2033-07-05
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	December 27, 1984	10,023,628	2033-07-05
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 15, 1985	10,023,628	2033-07-05
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 16, 1990	10,023,628	2033-07-05
Bel-mar Laboratories, Inc.	CHORIONIC GONADOTROPIN	chorionic gonadotropin	Injection	017054	March 26, 1974	10,023,628	2033-07-05
Fresenius Kabi Usa, Llc	CHORIONIC GONADOTROPIN	chorionic gonadotropin	For Injection	017067	March 05, 1973	10,023,628	2033-07-05